Patents Examined by Louis Wollenberger
-
Patent number: 7888497Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 14, 2004Date of Patent: February 15, 2011Assignee: Rosetta Genomics Ltd.Inventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7842800Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: April 2, 2004Date of Patent: November 30, 2010Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7829694Abstract: The present invention provides devices, small interfering RNA, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Spinocerebellar Ataxia Type 1, Type 2, Type 3, and/or dentatorubral-pallidoluysian atrophy.Type: GrantFiled: May 25, 2004Date of Patent: November 9, 2010Assignee: Medtronic, Inc.Inventor: William F. Kaemmerer
-
Patent number: 7812150Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.Type: GrantFiled: May 18, 2007Date of Patent: October 12, 2010Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
-
Patent number: 7777014Abstract: The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 34 and their use as pharmaceutical agents. The present invention also discloses a method for diagnosis of the ?786C/T-variance in the eNOS-gene.Type: GrantFiled: September 12, 2003Date of Patent: August 17, 2010Assignee: Avontec GmbHInventors: Marco Cattaruzza, Markus Hecker
-
Patent number: 7745610Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDK11.Type: GrantFiled: May 29, 2007Date of Patent: June 29, 2010Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7732591Abstract: The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.Type: GrantFiled: August 8, 2006Date of Patent: June 8, 2010Assignee: Medtronic, Inc.Inventors: William F. Kaemmerer, Michael D. Kaytor
-
Patent number: 7732592Abstract: The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK tyrosine kinase gene or fusion proteins thereof, and methods for using this animal model and cells for screening compounds or treatments for antitumor activity. In preferred embodiments, the animal is a transgenic mouse that expresses a human NPM-ALK gene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of the NPM-ALK transgene, whereby the mouse constitutively expresses a protein encoded by the NPM-ALK transgene. The animals and cells of the invention are useful in the study of NPM-ALK-dependent lymphomagenesis and plasma cell tumors and in the development of treatments for these conditions.Type: GrantFiled: September 18, 2007Date of Patent: June 8, 2010Assignee: New York UniversityInventors: Giorgio Inghirami, Roberto Chiarie
-
Patent number: 7713945Abstract: Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP?/? which exhibits enhanced survival following mismatched allogeneic marrow grafts.Type: GrantFiled: April 13, 2007Date of Patent: May 11, 2010Assignee: University of South FloridaInventor: William G. Kerr
-
Patent number: 7687616Abstract: The present invention describes a novel approach whereby small molecules may be used to modulate activity of microRNA and GAM oligonucleotides. This mode of therapy allows inter alia up regulation of a disease-related target gene of novel GAM oligonucleotides of the present invention, by countering the activity of a GAM oligonucleotides which naturally inhibits expression of that target gene. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 14, 2004Date of Patent: March 30, 2010Assignee: Rosetta Genomics LtdInventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7642248Abstract: A process is described for the delivery of a therapeutic polynucleotide to limb muscle tissue suffering from or potentially suffering from Muscular Dystrophy. The polynucleotide is inserted into a mammalian limb vessel such as an artery. Delivery efficiency and distribution is enhanced by combining injection of a solution containing the polynucleotide with the use of an externally applied cuff.Type: GrantFiled: March 30, 2007Date of Patent: January 5, 2010Assignee: Roche Madison IncInventors: Vladimir G. Budker, Jon A. Wolff
-
Patent number: 7619081Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to COPB2.Type: GrantFiled: May 30, 2007Date of Patent: November 17, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
Patent number: 7618948Abstract: The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject.Type: GrantFiled: October 19, 2005Date of Patent: November 17, 2009Assignee: Medtronic, Inc.Inventor: William F. Kaemmerer -
Patent number: 7612196Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.Type: GrantFiled: October 30, 2007Date of Patent: November 3, 2009Assignee: Dharmacon, Inc.Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
-
Patent number: 7605249Abstract: The present invention provides devices, small interfering RNA, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Spinocerebellar Ataxia Type 1, Type 2, Type 3, and/or dentatorubral-pallidoluysian atrophy.Type: GrantFiled: November 25, 2003Date of Patent: October 20, 2009Assignee: Medtronic, Inc.Inventor: William F. Kaemmerer
-
Patent number: 7579450Abstract: The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.Type: GrantFiled: April 26, 2005Date of Patent: August 25, 2009Assignee: Archemix Corp.Inventors: Paula Burmeister, Sharon Cload, John L. Diener, Anthony Dominic Keefe, Sara Chesworth Keene, Markus Kurz, H. A. Daniel Lagassé, Harold Nicholas Marsh, Pooja Sawhney, Chunhua Wang
-
Patent number: 7517865Abstract: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.Type: GrantFiled: April 26, 2006Date of Patent: April 14, 2009Assignee: Alnylam Pharmaceuticals, Inc.Inventor: Rachel Meyers
-
Patent number: 7507809Abstract: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.Type: GrantFiled: January 6, 2006Date of Patent: March 24, 2009Assignee: Alnylam Pharmaceuticals, Inc.Inventor: Rachel Meyers
-
Patent number: 7422853Abstract: The present invention provides novel methods for manipulating levels of expression of gene products using RNA interference (RNAi). The methods disclosed can be used to investigate gene function, to create disease-resistant organisms, and to treat disease.Type: GrantFiled: October 6, 2003Date of Patent: September 9, 2008Assignee: Myriad Genetics, Inc.Inventors: Liwen Huang, Herbert L. Ley, III
-
Patent number: 7423141Abstract: Sequences in human preproendothelin-1 mRNA are described against which antisense oligonucleotides can be used to inhibit the synthesis of endothelin-1. This inhibition of endothelin-1 synthesis may be used to treat diseases where excess production of endothelin-1 is an underlying cause of the symptoms.Type: GrantFiled: November 18, 2002Date of Patent: September 9, 2008Assignee: William Harvey Research Ltd.Inventors: Roger Corder, Adrian P. L. Smith, Timothy W. Higgenbottam, Martine Rothblatt, John Vane, Delphine Dominique Marthe Lees